Evidence map›Paper›PMID 25738469›Full record

ArticleMedicine2015

NOTCH3 gene polymorphism is associated with the prognosis of gliomas in Chinese patients.

Zhipeng Shen, Xuwei Hou, Bo Chen, Peng Chen, Qing Zhang

Abstract read
In one paragraph

Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/β-catenin signaling pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhipeng ShenFrom the Department of Neurosurgery, Children's Hospital, Zhejiang University School of Medicine, 57 Zhugan Lane, Hangzhou 310003, P.R. China (ZS); Hangzhou people hospital, Huansha Road 261, Hangzhou 310006, P.R.China (XH); Department of Rehabilitation, Hangzhou Hospital of Zhejiang Corps, Chinese People's Armed Police Forces, 86 Jiangnan Avenue, Hangzhou 310051, P.R. China (BC); Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, P.R. China (PC); Department of Cardiology, Children's Hospital; Zhejiang University School of Medicine, 57 Zhugan Lane, Hangzhou 310003, P.R. China (QZ).
Xuwei Hou
Bo Chen
Peng Chen
Qing Zhang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies show that NOTCH3 is involved in the glioma development and it is also a prognostic factor for glioma patients. However, the gene polymorphism of NOTCH3 in gliomas prognosis remains unknown.A total of 266 patients were enrolled into this study. The NOTCH3 gene polymorphism at 3 loci, including C>T polymorphism at nucleotide 381, C>A polymorphism at 474 and G>A polymorphism at 684 were determined. All patients received the surgical treatment and/or chemotherapy and/or radiotherapy.We found that the 684G>A polymorphism affects the tumor NOTCH3 expression level and is closely associated with a higher tumor grade, poorer tumor differentiation, and karnofsky performance score in these glioma patients. More importantly, the 684G>A polymorphism is significantly associated with the prognosis of these patients regardless of their treatment manner.Our study indicates that the NOTCH3 gene 684G>A polymorphism may be used as a prognosis marker for gliomas.

Indexed as

Asian PeopleBiomarkersChinaCombined Modality TherapyGenetic Predisposition to DiseaseGliomaHumansNeoplasm StagingPolymorphism, GeneticPrognosisReceptor, Notch3Receptors, NotchBiomarkersNOTCH3 protein, humanReceptor, Notch3Receptors, Notch

Identifiers

PMID25738469
PMCPMC4553966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.